Akums Drugs and Pharmaceuticals Limited: Comprehensive Company Profile

Background

Established in 2004 by Sanjeev Jain and Sandeep Jain, Akums Drugs and Pharmaceuticals Limited has emerged as India's largest Contract Development and Manufacturing Organization (CDMO). The company is dedicated to enhancing global healthcare by providing innovative, high-quality pharmaceutical solutions. With a mission to contribute to humanity's quest for longer, healthier, and happier lives through innovative healthcare products, Akums envisions becoming a globally admired pharmaceutical organization by offering research-based, affordable quality products to a larger global population.

Key Strategic Focus

Akums specializes in end-to-end pharmaceutical services, including formulation development, bioequivalence studies, clinical trials, and regulatory approvals. The company operates 15 state-of-the-art manufacturing facilities, producing a wide range of dosage forms across multiple therapeutic segments such as cardiology, neurology, gynecology, nephrology, anti-infectives, respiratory, analgesics, and multi-vitamins. Akums' robust R&D capabilities have led to over 220 innovative formulations, supported by more than 22 versatile platform technologies that enhance product development and differentiation.

Financials and Funding

In the fiscal year 2023-24, Akums reported revenue from operations of ₹4,178.18 crore, marking a 14.31% increase from the previous year. However, net profits declined to ₹0.79 crore, a 99% decrease from ₹97.81 crore in FY23, attributed to increased operational costs. The company's revenue composition for FY24 was as follows: CDMO contributed 78.17%, branded and generic formulations 16.73%, and APIs 5.08%.

In 2019, Akums received a $70 million investment from Quadria Capital, a Singapore-based private equity firm specializing in healthcare investments across South and Southeast Asia.

Pipeline Development

Akums has developed over 4,100 commercialized formulations across more than 60 dosage forms. Recent product launches include:

Lobeglitazone: An antidiabetic drug approved by the Drug Controller General of India (DCGI) for the treatment of diabetes in India.

Hydroxyurea Oral Suspension: A cost-effective treatment for sickle cell anemia, developed over two years at Akums' R&D center.

Doxylamine and Pyridoxine Extended-Release Tablets: Approved by the Central Drugs Standard Control Organisation (CDSCO) in India and the US FDA.

The company continues to focus on developing innovative formulations to address various therapeutic needs.

Technological Platform and Innovation

Akums' commitment to innovation is evident in its extensive R&D infrastructure, comprising four dedicated facilities, two of which are approved by the Department of Scientific and Industrial Research (DSIR), Government of India. The company employs over 400 scientists and has developed more than 220 innovative formulations supported by 22 versatile platform technologies. These proprietary technologies enable the development of differentiated products, enhancing therapeutic efficacy and patient compliance.

Leadership Team

Sanjeev Jain: Co-founder and Managing Director, with extensive experience in the pharmaceutical industry, overseeing strategic initiatives and operations.

Sandeep Jain: Co-founder and Managing Director, focusing on business development and corporate strategy.

Arushi Jain: Director – Growth and Strategy, contributing to the company's expansion and innovation efforts.

The leadership team is instrumental in driving Akums' growth and maintaining its position as a leading CDMO.

Leadership Changes

In 2024, Kanishk Jain was appointed as the Chairman of the Confederation of Indian Industry (CII) Uttarakhand State Council for the 2024-25 term, reflecting Akums' active participation in industry leadership.

Competitor Profile

Market Insights and Dynamics

The Indian pharmaceutical market is characterized by robust growth, driven by increasing healthcare needs, a growing population, and a strong manufacturing base. The CDMO sector, in particular, has seen significant expansion, with companies like Akums playing a pivotal role in supplying high-quality formulations to both domestic and international markets.

Competitor Analysis

Akums faces competition from several key players in the pharmaceutical manufacturing sector:

Intas Pharmaceuticals: Established in 1976, headquartered in Ahmedabad, Gujarat, Intas operates in the pharmaceuticals industry, generating approximately $1.8 billion more revenue than Akums.

Rubicon Research Pvt. Ltd.: Founded in 1999, based in Thane, Maharashtra, Rubicon also competes in the pharmaceuticals field but has 15,777 fewer employees than Akums.

Laborate Pharmaceuticals: Established in 1985 in Rohini, Delhi, Laborate operates within the pharmaceuticals industry, generating $362 million less revenue compared to Akums.

These competitors, along with others like Glenmark, Sun Pharma, and Mylan, contribute to a dynamic and competitive landscape in the pharmaceutical manufacturing sector.

Strategic Collaborations and Partnerships

Akums has engaged in several strategic partnerships to enhance its market position and innovation capacity:

Leiutis Pharmaceuticals LLP and Biophore India Pharmaceuticals: Collaborated to develop products for multiple therapies, addressing needs in CNS disorders, pain management, and hormonal disorders.

Microcore Research: Partnered to develop dietary supplements using natural eggshell membrane (NESM) for joint and connective tissue health.

Caregen: Teamed up to introduce specialty nutraceuticals and cosmeceuticals in India, aiming to revolutionize health and skincare solutions.

Jagdale Industries: Collaborated to market ready-to-drink nutritional beverages in India, expanding Akums' portfolio in the health and wellness segment.

These partnerships reflect Akums' commitment to innovation and expanding its product offerings.

Operational Insights

Akums' strategic considerations include:

Manufacturing Capabilities: Operating 15 state-of-the-art facilities with a total formulation manufacturing capacity of 64 billion units per annum, enabling the production of a wide range of dosage forms.

Quality Assurance: Adhering to global regulatory standards, including WHO-GMP, USFDA, EU-GMP, and TGA, ensuring product safety and efficacy.

Research and Development: Investing approximately ₹50 crore annually in R&D, focusing on developing innovative formulations and improving product quality.

These operational strengths position Akums as a leader in the pharmaceutical manufacturing industry.

Strategic Opportunities and Future Directions

Akums aims to:

Expand Market Share: Targeting a revenue of ₹10,000 crore and a 20% market share in the next 4-5 years.

Diversify Product Portfolio: Venturing into new therapeutic areas such as neurology, psychiatry, and orphan diseases to tap into previously untapped market segments.

Enhance Global Presence: Expanding exports to high-value, semi-regulated markets such as MENA, LATAM, and Eastern Europe, with plans to more than double export contributions in the next 4-5 years.

By leveraging its strengths in manufacturing, R&D, and strategic partnerships, Akums is well-positioned to achieve these objectives.